Atlas Venture, Pfizer Ventures, Tekla Capital Management LLC, BioInnovation Capital
Founders
Gerhard Koenig
Company Description
Arkuda Therapeutics is a biotechnology company leveraging new insights into progranulin and lysosomal biology to develop medicines to change the trajectory of neurodegenerative disease. Arkuda's lead compounds aim to correct progranulin deficiency and lysosomal dysfunction in GRN-related frontotemporal dementia (FTD-GRN), a genetically-defined subtype of frontotemporal dementia caused by an autosomal dominant mutation in the GRN gene.
Market
Neurodegenerative diseases
Location
Cambridge,
MA,
USA
Coinvestors
Atlas Venture, Pfizer Ventures, funds managed by Tekla Capital Management LLC, BioInnovation Capital